rating costs and expenses:
Cost of goods sold 5,349 27,457 18,020 123,469
Cost of idle Exubera
manufacturing capacity 6,821
Research and development 38,265 35,773 109,138 114,265
General and administrative 12,149 12,426 36,951 42,339
Amortization of other
intangible assets 237 237 710 710
Total operating costs and
expenses 56,000 75,893 171,640 280,783
Loss from operations (34,561) (19,572) (109,808) (73,529)
Non-operating income (expense):
Interest income 2,375 5,519 10,578 16,444
Interest expense (3,988) (4,773) (11,835) (14,408)
Loss on equity investment (705) - (705) -
Other income (expense), net 117 206 1,188 189
Total non-operating income
(expense) (2,201) 952 (774) 2,225
Loss before provision for income
taxes (36,762) (18,620) (110,582) (71,304)
Provision for income taxes 276 - 536 500
Net loss $(37,038) $(18,620) $(111,118) $(71,804)
Basic and diluted net loss per
share $(0.40) $(0.20) $(1.20) $(0.78)
Shares used in computing basic
and diluted net loss per share 92,415 92,028 92,408 91,764
NEKTAR THERAPEUTICS
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
September 30, December 31,
2008 2007
'/>"/>
SOURCE Nektar Therapeutics Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related medicine news :1.
Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets2.
Nektar Therapeutics Announces Second Quarter 2008 Results3.
Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer4.
Nektar Therapeutics Announces First Quarter 2008 Results5.
FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform6.
Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results7.
Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets8.
Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City9.
Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia10.
Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York11.
Nektar Therapeutics Announces Third Quarter 2007 Financial Results